BIOMAT Database Logo BIOMAT Database Logo

[Fast-dissolving sublingual tablets of piroxicam versus naproxen in the treatment of recurrent acute osteoarthrosis. Multicenter clinical trial]. 1994

G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Cattedra e Scuola di Specializzazione in Reumatologia, Università degli Studi di Chieti.

An open comparative study was carried out to evaluate the efficacy and safety of piroxicam FDDF, for sublingual administration, versus naproxen in the treatment of osteoarthritis. Sixty-one patients with acute-phase osteoarthritis involving various joints are reported. They were treated with 20 mg/day piroxicam FDDF or with 1000 mg/day naproxen for a total of 4 weeks. Drug efficacy was evaluated on the base of the variation of spontaneous pain, pain on motion, functional limitation and capacity to perform a specific activity. The intensity of spontaneous pain on the first day showed a statistically significant improvement with both drugs, but the onset of analgesia was only after 15 minutes with piroxicam and after 1 hour with naproxen. The improvement in pain intensity increased on the first day and until the 7th day with both drugs, but the comparative analysis between the analgesic efficacy of the two treatments proved to be favourable to piroxicam. On the 7th day, pain on motion and the capacity to perform a specific activity showed a statistically significant improvement with both drugs, but the comparative analysis between the two treatments proved to be favourable to piroxicam. The two drugs showed the same efficacy in functional restriction. The local and systemic tolerability of piroxicam was good. Only 5 patients experienced 6 systemic side-effects, and 1 patients showed local side-effects, but 11 patients of the naproxen group showed 12 systemic side-effects. Thus piroxicam showed a better analgesic and anti-inflammatory efficacy than naproxen. Piroxicam proved to have a better systemic tolerability than naproxen. The local tolerability of piroxicam FDDF was good.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009288 Naproxen An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. Aleve,Anaprox,Methoxypropiocin,Naprosin,Naprosyn,Naproxen Sodium,Proxen,Sodium Naproxenate,Synflex,Naproxenate, Sodium,Sodium, Naproxen
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010894 Piroxicam A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. CP-16171,Feldene,CP 16171,CP16171
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
[Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis].
December 1993, La Clinica terapeutica,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
[FDDF (fast dissolving dosage form) piroxicam for sublingual administration in the treatment of rheumatoid arthritis].
December 1994, Minerva medica,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Orally disintegrating tablets, fast-dissolving, buccal and sublingual formulations.
June 2018, Pharmaceutical development and technology,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study.
June 2019, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes.
May 1988, The American journal of medicine,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Piroxicam versus naproxen in the treatment of painful shoulder.
January 1986, Pharmatherapeutica,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain.
January 1996, Clinical therapeutics,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets.
January 2022, Current therapeutic research, clinical and experimental,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Piroxicam fast-dissolving dosage form vs diclofenac sodium in the treatment of acute renal colic: a double-blind controlled trial.
January 1998, British journal of urology,
G Consoli, and M Covelli, and L Di Matteo, and R Marcolongo, and G Tirri, and G La Montagna, and V Pipitone
Clinical trial of rapidly dissolving theophylline tablets.
April 1974, The Medical journal of Australia,
Copied contents to your clipboard!